JPWO2021051003A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021051003A5
JPWO2021051003A5 JP2022515885A JP2022515885A JPWO2021051003A5 JP WO2021051003 A5 JPWO2021051003 A5 JP WO2021051003A5 JP 2022515885 A JP2022515885 A JP 2022515885A JP 2022515885 A JP2022515885 A JP 2022515885A JP WO2021051003 A5 JPWO2021051003 A5 JP WO2021051003A5
Authority
JP
Japan
Prior art keywords
composition
concentration
item
methotrexate
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022515885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548226A (ja
JP7682512B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050565 external-priority patent/WO2021051003A1/en
Publication of JP2022548226A publication Critical patent/JP2022548226A/ja
Publication of JPWO2021051003A5 publication Critical patent/JPWO2021051003A5/ja
Application granted granted Critical
Publication of JP7682512B2 publication Critical patent/JP7682512B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022515885A 2019-09-13 2020-09-11 メトトレキサートの眼科用製剤 Active JP7682512B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900060P 2019-09-13 2019-09-13
US62/900,060 2019-09-13
US202063044288P 2020-06-25 2020-06-25
US63/044,288 2020-06-25
PCT/US2020/050565 WO2021051003A1 (en) 2019-09-13 2020-09-11 Ophthalmic formulations of methotrexate

Publications (3)

Publication Number Publication Date
JP2022548226A JP2022548226A (ja) 2022-11-17
JPWO2021051003A5 true JPWO2021051003A5 (enrdf_load_stackoverflow) 2023-09-20
JP7682512B2 JP7682512B2 (ja) 2025-05-26

Family

ID=74866765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515885A Active JP7682512B2 (ja) 2019-09-13 2020-09-11 メトトレキサートの眼科用製剤

Country Status (9)

Country Link
US (3) US20220370460A1 (enrdf_load_stackoverflow)
EP (1) EP4028015A4 (enrdf_load_stackoverflow)
JP (1) JP7682512B2 (enrdf_load_stackoverflow)
KR (1) KR20220062617A (enrdf_load_stackoverflow)
CN (1) CN114423432A (enrdf_load_stackoverflow)
AU (1) AU2020344685A1 (enrdf_load_stackoverflow)
CA (1) CA3149467A1 (enrdf_load_stackoverflow)
IL (1) IL291228A (enrdf_load_stackoverflow)
WO (1) WO2021051003A1 (enrdf_load_stackoverflow)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
HK1217439A1 (zh) 2013-01-23 2017-01-13 Aldeyra Therapeutics, Inc. 与毒性醛相关的疾病和治疗
CA2996183A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
EP3962894A4 (en) 2019-05-02 2023-01-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
CN114423432A (zh) 2019-09-13 2022-04-29 奥尔德拉医疗公司 甲氨蝶呤的眼用制剂
CN115697336A (zh) 2020-05-13 2023-02-03 奥尔德拉医疗公司 药物制剂及其用途
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods
WO2024129979A1 (en) * 2022-12-14 2024-06-20 Aldeyra Therapeutics, Inc. Methotrexate treatment methods

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253243A1 (en) 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050148512A1 (en) 2003-11-10 2005-07-07 Angiotech International Ag Medical implants and fibrosis-inducing agents
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
EP2452670A1 (en) 2004-10-01 2012-05-16 Ramscor, Inc. Conveniently implantable sustained release drug compositions
EP1853259A1 (en) * 2005-02-09 2007-11-14 Macusight, Inc. Formulations for ocular treatment
KR20080018874A (ko) 2005-04-27 2008-02-28 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 인간 질병과 관련된 돌연변이 단백질의 분해 촉진을 위한물질 및 방법
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US20090081277A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
US20110200662A1 (en) 2008-10-22 2011-08-18 Arnold Glazier Method For The Treatment Of Proliferative Disorders Of The Eye
BRPI1008920A2 (pt) * 2009-03-03 2015-08-25 Alcon Res Ltd Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho
GB201200192D0 (en) * 2012-01-06 2012-02-22 Rosemont Pharmaceuticals Ltd Methotrexate composition
EP2890389A1 (en) * 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
US20140105956A1 (en) 2012-10-11 2014-04-17 Rupak BANERJEE Biodegradable polymer based microimplant for ocular drug delivery
CA3240136A1 (en) 2012-11-08 2014-05-15 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
CA2991921C (en) * 2014-07-30 2023-08-08 Massachusetts Eye And Ear Infirmary Methotrexate for proliferative vitreoretinopathy
GB201419261D0 (en) 2014-10-29 2014-12-10 Therakind Ltd Formulations
GB201522441D0 (en) 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
WO2018201146A1 (en) 2017-04-28 2018-11-01 Case Western Reserve University Compounds and methods of treating retinal degeneration
AU2019226571A1 (en) 2018-03-01 2020-10-01 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for suppressing toxic endoplasmic reticulum stress
CN114423432A (zh) 2019-09-13 2022-04-29 奥尔德拉医疗公司 甲氨蝶呤的眼用制剂
JP7676429B2 (ja) 2020-02-26 2025-05-14 ケース ウエスタン リザーブ ユニバーシティ 誤って折り畳まれたタンパク質の眼疾患を治療するための組成物及び方法

Similar Documents

Publication Publication Date Title
JP7682512B2 (ja) メトトレキサートの眼科用製剤
US12016867B2 (en) Methods of treating inflammation and/or pain
AU2015257651B2 (en) Compounds for treating ophthalmic diseases and disorders
Raghava et al. Periocular routes for retinal drug delivery
Bochot et al. Liposomes for intravitreal drug delivery: a state of the art
ES2345018T3 (es) Composiciones y procedimientos para tratar el segmento posterior del ojo.
Gan et al. Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial
JP5726774B2 (ja) ロテプレドノールエタボネートおよびトブラマイシンの局所眼科用懸濁液
US20030143259A1 (en) Topical treatment or prevention of ocular infections
JPWO2021051003A5 (enrdf_load_stackoverflow)
Keenan Steroids in the management of infectious keratitis
RU2006124557A (ru) Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний
JP2021152002A5 (enrdf_load_stackoverflow)
US20250120985A1 (en) Method of treating diabetic macular edema
EP2968383A1 (en) Concentrated aqueous azalide formulations
Miserocchi et al. Treatment of Intermediate Uveitis
Agarwal et al. Corticosteroids
Bakri et al. Antiangiogenic agents: intravitreal injection
RU2025122399A (ru) Способ лечения операционных осложнений при хирургическом лечении катаракты
Escott et al. Medical Management of CME Associated with Uveitis
JPWO2021041989A5 (enrdf_load_stackoverflow)